Discover
SCNI
Scinai Immunotherapeutics Ltd.
0.47
1 x 0.40
1 x 0.56
bid
ask
-
0.05
9.05%
1 @ 04:00 PM
0.49 +0.02 (3.22%)
| Ytd | -93.38% | |
| 1y | -96.77% |
0.47
day range
0.55
0.47
52 week range
15.50
| Open | 0.55 | Prev Close | 0.52 | Low | 0.47 | High | 0.55 | Mkt Cap | 1.24M |
| Vol | 52.93K | Avg Vol | 2.15M | EPS | 28.07 | P/E | 0.02 | Forward P/E | N/A |
| Beta | 2.46 | Short Ratio | 0.09 | Inst. Own | 2.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.58 | 200-d Avg | 4.51 | 1yr Est | 700.00 |
| Income Statement | |||
| Total Revenue | 460.00K | ||
| Revenues (USD) | 460.00K | ||
| Cost of Revenue | 1.71M | ||
| Gross Profit | -1.25M | ||
| Operating Expenses | 894.00K | ||
| Research and Development Expense | 211.00K | ||
| Selling, General and Administrative Expense | 683.00K | ||
| Operating Income | -2.15M | ||
| Net Income | -2.00M | ||
| Net Income Common Stock | -2.00M | ||
| Net Income Common Stock (USD) | -2.00M | ||
| Consolidated Income | -2.00M | ||
| Earning Before Interest & Taxes (EBIT) | -2.00M | ||
| Earning Before Interest & Taxes (USD) | -2.00M | ||
| Weighted Average Shares | 30.19B | ||
| Weighted Average Shares Diluted | 30.19B | ||
| Balance Sheet | |||
| Cash and Equivalents | 2.85M | ||
| Cash and Equivalents (USD) | 2.85M | ||
| Trade and Non-Trade Receivables | 74.00K | ||
| Current Assets | 3.49M | ||
| Property, Plant & Equipment Net | 13.69M | ||
| Total Assets | 17.18M | ||
| Debt Current | 369.00K | ||
| Total Debt | 3.58M | ||
| Current Liabilities | 2.23M | ||
| Debt Non-Current | 3.21M | ||
| Total Liabilities | 5.44M | ||
| Accumulated Retained Earnings (Deficit) | -124.27M | ||
| Accumulated Other Comprehensive Income | -2.14M | ||
| Shareholders Equity | 11.73M | ||
| Shareholders Equity (USD) | 11.73M | ||
| Assets Non-Current | 13.69M | ||
| Total Debt (USD) | 3.58M | ||
| Liabilities Non-Current | 3.21M | ||
| Trade and Non-Trade Payables | 1.86M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 586.00K | ||
| Net Cash Flow from Financing | 2.32M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -261.00K | ||
| Capital Expenditure | -112.00K | ||
| Issuance (Purchase) of Equity Shares | 2.32M | ||
| Net Cash Flow from Investing | -112.00K | ||
| Net Cash Flow from Operations | -2.46M | ||
| Share Based Compensation | 58.00K | ||